These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


210 related items for PubMed ID: 11150394

  • 1. D-Ribose as a supplement for cardiac energy metabolism.
    Pauly DF, Pepine CJ.
    J Cardiovasc Pharmacol Ther; 2000 Oct; 5(4):249-58. PubMed ID: 11150394
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog.
    Mauser M, Hoffmeister HM, Nienaber C, Schaper W.
    Circ Res; 1985 Feb; 56(2):220-30. PubMed ID: 3918804
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ribose-enhanced myocardial recovery following ischemia in the isolated working rat heart.
    Pasque MK, Spray TL, Pellom GL, Van Trigt P, Peyton RB, Currie WD, Wechsler AS.
    J Thorac Cardiovasc Surg; 1982 Mar; 83(3):390-8. PubMed ID: 6174831
    [Abstract] [Full Text] [Related]

  • 8. The patented uses of D-ribose in cardiovascular diseases.
    Shecterle LM, Terry KR, St Cyr JA.
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):138-42. PubMed ID: 20236088
    [Abstract] [Full Text] [Related]

  • 9. Metabolic recovery following temporary regional myocardial ischemia in the rat.
    Ibel H, Zimmer HG.
    J Mol Cell Cardiol; 1986 Oct; 18 Suppl 4():61-5. PubMed ID: 3097331
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. D-ribose, a metabolic substrate for congestive heart failure.
    Wagner S, Herrick J, Shecterle LM, St Cyr JA.
    Prog Cardiovasc Nurs; 2009 Jun; 24(2):59-60. PubMed ID: 19523159
    [Abstract] [Full Text] [Related]

  • 12. Preischemic administration of ribose to delay the onset of irreversible ischemic injury and improve function: studies in normal and hypertrophied hearts.
    Wallen WJ, Belanger MP, Wittnich C.
    Can J Physiol Pharmacol; 2003 Jan; 81(1):40-7. PubMed ID: 12665256
    [Abstract] [Full Text] [Related]

  • 13. L-propionylcarnitine does not affect myocardial metabolic or functional response to chronotropic and inotropic stimulation after repetitive ischemia in anesthetized pigs.
    Duncker DJ, Sassen LM, Bartels GL, van Meegen JR, McFalls EO, Krams R, Bezstarosti K, Lamers JM, Verdouw PD.
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):488-98. PubMed ID: 7504143
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of ribose on cardiac adenine nucleotides in a donor model for heart transplantation.
    Müller C, Zimmer H, Gross M, Gresser U, Brotsack I, Wehling M, Pliml W.
    Eur J Med Res; 1998 Dec 16; 3(12):554-8. PubMed ID: 9889175
    [Abstract] [Full Text] [Related]

  • 18. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine.
    El Alaoui-Talibi Z, Guendouz A, Moravec M, Moravec J.
    Am J Physiol; 1997 Apr 16; 272(4 Pt 2):H1615-24. PubMed ID: 9139943
    [Abstract] [Full Text] [Related]

  • 19. [Chronic myocardial ischemia--hibernating myocardium: characteristics and limits].
    Heusch G, Schulz R.
    Z Kardiol; 1993 Apr 16; 82 Suppl 5():133-41. PubMed ID: 8154154
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of cardioprotective effect of orotic acid.
    Rosenfeldt FL, Richards SM, Lin Z, Pepe S, Conyers RA.
    Cardiovasc Drugs Ther; 1998 Sep 16; 12 Suppl 2():159-70. PubMed ID: 9794090
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.